• 1
    Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest. 2000; 117: 124755.
  • 2
    Rizk NP, Venkatraman E, Bains MS, et al . American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007; 25: 50712.
  • 3
    Roldo C, Missiaglia E, Hagan JP, et al . MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006; 24: 467784.
  • 4
    Tomlinson R, Gray L. The histological structure of some lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955; 9: 53949.
  • 5
    Almog N, Ma L, Raychowdhury R, et al . Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009; 69: 83644.
  • 6
    Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 2001; 61: 60504.
  • 7
    Petit AM, Rak J, Hung MC, et al . Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997; 151: 152330.
  • 8
    Casanova ML, Larcher F, Casanova B, et al . A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res. 2002; 62: 34027.
  • 9
    Rak J, Mitsuhashi Y, Bayko L, et al . Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995; 55: 457580.
  • 10
    Mizukami Y, Li J, Zhang X, et al . Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 2004; 64: 176572.
  • 11
    Blancher C, Moore JW, Talks KL, et al . Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 2000; 60: 710613.
  • 12
    Liu Y, Cox SR, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res. 1995; 77: 63843.
  • 13
    Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998; 17: 300515.
  • 14
    Shweiki D, Itin A, Soffer D, et al . Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359: 8435.
  • 15
    Maxwell PH, Dachs GU, Gleadle JM, et al . Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997; 94: 81049.
  • 16
    Skinner SA, Frydman GM, O’Brien PE. Microvascular structure of benign and malignant tumors of the colon in humans. Dig Dis Sci. 1995; 40: 37384.
  • 17
    Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998; 58: 140816.
  • 18
    Li C, Wright MM, Jackson RM. Reactive species mediated injury of human lung epithelial cells after hypoxia-reoxygenation. Exp Lung Res. 2002; 28: 37389.
  • 19
    Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 3847.
  • 20
    Anderson AR, Weaver AM, Cummings PT, et al . Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell. 2006; 127: 90515.
  • 21
    Graeber TG, Osmanian C, Jacks T, et al . Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; 379: 8891.
  • 22
    Kim CY, Tsai MH, Osmanian C, et al . Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res. 1997; 57: 42004.
  • 23
    Kondo A, Safaei R, Mishima M, et al . Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res. 2001; 61: 76037.
  • 24
    Kim KJ, Li B, Winer J, et al . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362: 8414.
  • 25
    Claffey KP, Brown LF, Del Aguila LF, et al . Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996; 56: 17281.
  • 26
    Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy. Radiat Res. 1997; 147: 54150.
  • 27
    Kaanders JH, Wijffels KI, Marres HA, et al . Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 2002; 62: 706674.
  • 28
    Kaanders JH, Pop LA, Marres HA, et al . ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002; 52: 76978.
  • 29
    Overgaard J, Hansen HS, Overgaard M, et al . A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85. Radiother Oncol. 1998; 46: 13546.
  • 30
    Overgaard J, Eriksen JG, Nordsmark M, et al . Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005; 6: 75764.
  • 31
    Rischin D, Hicks RJ, Fisher R, et al . Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006; 24: 2098104.
  • 32
    Scott EN, Meinhardt G, Jacques C, et al . Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs. 2007; 16: 36779.
  • 33
    Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26: 22539.
  • 34
    Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001; 93: 26676.
  • 35
    Hockel M, Knoop C, Schlenger K, et al . Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993; 26: 4550.
  • 36
    Gatenby RA, Kessler HB, Rosenblum JS, et al . Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988; 14: 8318.
  • 37
    Fyles A, Milosevic M, Hedley D, et al . Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002; 20: 6807.
  • 38
    Hockel M, Schlenger K, Aral B, et al . Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56: 450915.
  • 39
    Hockel M, Schlenger K, Hockel S, et al . Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999; 59: 45258.
  • 40
    Knocke TH, Weitmann HD, Feldmann HJ, et al . Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol. 1999; 53: 99104.
  • 41
    Lyng H, Sundfor K, Trope C, et al . Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res. 2000; 6: 110412.
  • 42
    Nordsmark M, Loncaster J, Aquino-Parsons C, et al . The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol. 2006; 80: 12331.
  • 43
    Colpaert CG, Vermeulen PB, Fox SB, et al . The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat. 2003; 81: 13747.
  • 44
    Couvelard A, O’Toole D, Leek R, et al . Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology. 2005; 46: 66876.
  • 45
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 5770.
  • 46
    Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 1994; 369: 4148.
  • 47
    Feldser D, Agani F, Iyer NV, et al . Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999; 59: 39158.
  • 48
    Dong Z, Venkatachalam MA, Wang J, et al . Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem. 2001; 276: 187029.
  • 49
    Seimiya H, Tanji M, Oh-hara T, et al . Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. Biochem Biophys Res Commun. 1999; 260: 36570.
  • 50
    Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006; 66: 6699707.
  • 51
    Swietach P, Wigfield S, Cobden P, et al . Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem. 2008; 283: 2047383.
  • 52
    Erler JT, Bennewith KL, Cox TR, et al . Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009; 15: 3544.
  • 53
    Erler JT, Bennewith KL, Nicolau M, et al . Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006; 440: 12226.
  • 54
    Mole DR, Blancher C, Copley RR, et al . Genome-wide association of hypoxia-inducible factor (HIF)-1{alpha} and HIF-2{alpha} DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009; 284: 1676775.
  • 55
    Kim W. The VHL tumor suppressor protein, HIF and cancer. J Cell Mol Med. 2009.
  • 56
    Boyd JM, Gallo GJ, Elangovan B, et al . Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene. 1995; 11: 19218.
  • 57
    Koong AC, Denko NC, Hudson KM, et al . Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000; 60: 8837.
  • 58
    Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, et al . Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. J Biol Chem. 2001; 276: 1530615.
  • 59
    Nishiwaki T, Daigo Y, Kawasoe T, et al . Isolation and mutational analysis of a novel human cDNA, DEC1 (deleted in esophageal cancer 1), derived from the tumor suppressor locus in 9q32. Genes Chromosomes Cancer. 2000; 27: 16976.
  • 60
    Chi JT, Wang Z, Nuyten DS, et al . Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006; 3: 395409.
  • 61
    Kim SJ, Rabbani ZN, Vollmer RT, et al . Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res. 2004; 10: 792533.
  • 62
    Couvelard A, O’Toole D, Turley H, et al . Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005; 92: 94101.
  • 63
    Loncaster JA, Harris AL, Davidson SE, et al . Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001; 61: 63949.
  • 64
    Sowter HM, Raval RR, Moore JW, et al . Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 2003; 63: 61304.
  • 65
    Chen C, Pore N, Behrooz A, et al . Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 2001; 276: 951925.
  • 66
    Hu CJ, Wang LY, Chodosh LA, et al . Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003; 23: 936174.
  • 67
    Dales JP, Garcia S, Meunier-Carpentier S, et al . Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer. 2005; 116: 7349.
  • 68
    Generali D, Berruti A, Brizzi MP, et al . Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006; 12: 45628.
  • 69
    Yamamoto Y, Ibusuki M, Okumura Y, et al . Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008; 110: 46575.
  • 70
    Trastour C, Benizri E, Ettore F, et al . HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer. 2007; 120: 14518.
  • 71
    Bos R, Van Der Groep P, Greijer AE, et al . Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003; 97: 157381.
  • 72
    Schindl M, Schoppmann SF, Samonigg H, et al . Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002; 8: 18317.
  • 73
    Helczynska K, Larsson AM, Holmquist Mengelbier L, et al . Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 2008; 68: 921220.
  • 74
    Gruber G, Greiner RH, Hlushchuk R, et al . Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res. 2004; 6: R1918.
  • 75
    Chen G, Ray R, Dubik D, et al . The E1B 19K/Bcl-2-binding protein Nip3 is a dimeric mitochondrial protein that activates apoptosis. J Exp Med. 1997; 186: 197583.
  • 76
    Tan EY, Campo L, Han C, et al . BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res. 2007; 13: 46774.
  • 77
    Hutchison GJ, Valentine HR, Loncaster JA, et al . Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res. 2004; 10: 840512.
  • 78
    Liao D, Corle C, Seagroves TN, et al . Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007; 67: 56372.
  • 79
    Rofstad EK, Galappathi K, Mathiesen B, et al . Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res. 2007; 13: 19718.
  • 80
    Ginouves A, Ilc K, Macias N, et al . PHDs overactivation during chronic hypoxia “desensitizes” HIFalpha and protects cells from necrosis. Proc Natl Acad Sci USA. 2008; 105: 474550.
  • 81
    Martinive P, Defresne F, Bouzin C, et al . Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 2006; 66: 1173644.
  • 82
    Willam C, Warnecke C, Schefold JC, et al . Inconsistent effects of acidosis on HIF-alpha protein and its target genes. Pflugers Arch. 2006; 451: 53443.
  • 83
    Iakovlev VV, Pintilie M, Morrison A, et al . Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest. 2007; 87: 120617.
  • 84
    Vleugel MM, Greijer AE, Shvarts A, et al . Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol. 2005; 58: 1727.
  • 85
    Li YM, Zhou BP, Deng J, et al . A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res. 2005; 65: 325763.
  • 86
    Wykoff CC, Beasley NJ, Watson PH, et al . Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000; 60: 707583.
  • 87
    Winter SC, Shah KA, Han C, et al . The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer. 2006; 107: 75766.
  • 88
    Kaluz S, Kaluzova M, Chrastina A, et al . Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3’-kinase. Cancer Res. 2002; 62: 446977.
  • 89
    Nordsmark M, Eriksen JG, Gebski V, et al . Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol. 2007; 83: 38997.
  • 90
    Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, et al . Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res. 2005; 65: 725966.
  • 91
    Ord JJ, Agrawal S, Thamboo TP, et al . An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol. 2007; 178: 67782.
  • 92
    McShane LM, Altman DG, Sauerbrei W, et al . REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93: 38791.
  • 93
    Van De Vijver MJ, He YD, Van’t Veer LJ, et al . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347: 19992009.
  • 94
    Wang Y, Klijn JG, Zhang Y, et al . Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365: 6719.
  • 95
    Seigneuric R, Starmans MH, Fung G, et al . Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol. 2007; 83: 37482.
  • 96
    Zhang C, Kawauchi J, Adachi MT, et al . Activation of JNK and transcriptional repressor ATF3/LRF1 through the IRE1/TRAF2 pathway is implicated in human vascular endothelial cell death by homocysteine. Biochem Biophys Res Commun. 2001; 289: 71824.
  • 97
    Kitamuro T, Takahashi K, Ogawa K, et al . Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. J Biol Chem. 2003; 278: 912533.
  • 98
    Nuyten DS, Kreike B, Hart AA, et al . Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006; 8: R62.
  • 99
    Chen JL, Lucas JE, Schroeder T, et al . The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet. 2008; 4: e1000293.
  • 100
    Winter SC, Buffa FM, Silva P, et al . Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007; 67: 34419.
  • 101
    Hurwitz H, Fehrenbacher L, Novotny W, et al . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 233542.
  • 102
    Murat A, Migliavacca E, Hussain SF, et al . Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. 2009; 4: e5947.
  • 103
    Walsh S, Gill C, O’Neill A, et al . Hypoxia increases normal prostate epithelial cell resistance to receptor-mediated apoptosis via AKT activation. Int J Cancer. 2009; 124: 18718.
  • 104
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 85766.
  • 105
    Camps C, Buffa FM, Colella S, et al . hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14: 13408.
  • 106
    Kulshreshtha R, Ferracin M, Wojcik SE, et al . A microRNA signature of hypoxia. Mol Cell Biol. 2007; 27: 185967.
  • 107
    Brazma A, Hingamp P, Quackenbush J, et al . Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001; 29: 36571.
  • 108
    Shi L, Reid LH, Jones WD, et al . The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006; 24: 115161.
  • 109
    Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007; 26: 2418.
  • 110
    Williams KJ, Telfer BA, Xenaki D, et al . Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol. 2005; 75: 8998.
  • 111
    Dische S, Saunders M, Barrett A, et al . A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997; 44: 12336.
  • 112
    Koukourakis MI, Bentzen SM, Giatromanolaki A, et al . Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 2006; 24: 72735.
  • 113
    Zhu Y, Denhardt DT, Cao H, et al . Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene. 2005; 24: 655563.
  • 114
    Fyfe GA, Hurwitz H, Fehrenbacher L, et al . Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol. 2004; 22: 3617.
  • 115
    Minn H, Gronroos TJ, Komar G, et al . Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des. 2008; 14: 293242.